Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 377

The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.

Neoadjuvant Modified FOLFOX6 With or Without Radiation Versus Fluorouracil Plus Radiation for Locally Advanced Rectal Cancer: Final Results of the Chinese FOWARC Trial

Open access
Deng, Yanhong, Chi, Pan, Lan, Ping, Wang, Lei, Chen, Weiqing, Cui, Long, Chen, Daoda, Cao, Jie, Wei, Hongbo, Peng, Xiang, Huang, Zonghai, Cai, Guanfu, Zhao, Ren, Huang, Zhongcheng, Xu, Lin, Zhou, Hongfeng, Wei, Yisheng, Zhang, Hao, Zheng, Jian, Huang, Yan, Zhou, Zhiyang, Cai, Yue, Kang, Liang, Huang, Meijin, Wu, Xiaojian, Peng, Junsheng, Ren, Donglin, Wang, Jianping·2019·Journal of Clinical Oncology

Abstract

PURPOSE: In the multicenter, open-label, phase III FOWARC trial, modified infusional fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) plus radiotherapy resulted in a higher pathologic complete response rate than fluorouracil plus radiotherapy in Chinese patients with locally advanced rectal cancer. Here, we report the final results. METHODS: Adults ages 18 to 75 years with stage II/III rectal cancer were randomly assigned (1:1:1) to five cycles of infusional fluorouracil (leucovorin 400 mg/m 2, fluorouracil 400 mg/m 2, and fluorouracil 2.4 g/m 2 over 48 hours) plus radiotherapy (46.0 to 50.4 Gy delivered in 23 to 25 fractions during cycles 2 to 4) followed by surgery and seven cycles of infusional fluorouracil, the same treatment plus intravenous oxaliplatin 85 mg/m 2 on day 1 of each cycle (mFOLFOX6), or four to six cycles of mFOLFOX6 followed by surgery and six to eight cycles of mFOLFOX6. The primary end point was 3-year disease-free survival (DFS). RESULTS: In total, 495 patients were randomly assigned to treatment. After a median follow-up of 45.2 months, DFS events were reported in 46, 39, and 46 patients in the fluorouracil plus radiotherapy, mFOLFOX6 plus radiotherapy, and mFOLFOX6 arms. In each arm, the probability of 3-year DFS was 72.9%, 77.2%, and 73.5% ( P = .709 by the log-rank test), the 3-year probability of local recurrence after R0/1 resection was 8.0%, 7.0%, and 8.3% ( P = .873 by the log-rank test), and the 3-year overall survival rate was 91.3%, 89.1%, and 90.7% ( P = .971 by log-rank test), respectively. CONCLUSION: mFOLFOX6, with or without radiation, did not significantly improve 3-year DFS versus fluorouracil with radiation in patients with locally advanced rectal cancer. No significant difference in outcomes was found between mFOLFOX6 without radiotherapy and fluorouracil with radiotherapy, which requires additional investigation of the role of radiotherapy in these regimens.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.18.02309

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 24 references

Cited by

See all 377

Metadata

Authors
Deng, Y., Chi, P., Lan, P., Wang, L., Chen, W., Cui, L., Chen, D., Cao, J., Wei, H., Peng, X., Huang, Z., Cai, G., Zhao, R., Huang, Z., Xu, L., Zhou, H., Wei, Y., Zhang, H., Zheng, J., Huang, Y., Zhou, Z., Cai, Y., Kang, L., Huang, M., Wu, X., Peng, J., Ren, D., & Wang, J.
Venue
Journal of Clinical Oncology
Published
2019-12-01
Volume
37
Issue
34
Pages
3223-3233
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2976277306
Cited by
377
References
24
FWCI
15.05
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Neoadjuvant Modified FOLFOX6 With or Without Radiation Versus Fluorouracil Plus Radiation for Locally Advanced Rectal Cancer: Final Results of the Chinese FOWARC Trial. https://app.cochat.ai/papers/10.1200/jco.18.02309
The paper
Deng, Y., Chi, P., Lan, P., Wang, L., Chen, W., Cui, L., Chen, D., Cao, J., Wei, H., Peng, X., Huang, Z., Cai, G., Zhao, R., Huang, Z., Xu, L., Zhou, H., Wei, Y., Zhang, H., Zheng, J., . . . Wang, J. (2019). Neoadjuvant Modified FOLFOX6 With or Without Radiation Versus Fluorouracil Plus Radiation for Locally Advanced Rectal Cancer: Final Results of the Chinese FOWARC Trial. Journal of Clinical Oncology. https://doi.org/10.1200/jco.18.02309

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.